Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 11:34:138.
doi: 10.1186/s13046-015-0254-2.

Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice

Affiliations

Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice

Xinli Li et al. J Exp Clin Cancer Res. .

Abstract

Background: Tumor progression locus 2 (TPL2), a serine-threonine kinase, functions as a critical regulator of inflammatory pathways and mediates oncogenic events. The potential role of Tpl2 in nonalcoholic fatty liver disease (NAFLD) associated hepatocellular carcinoma (HCC) development remains unknown.

Methods: Both wild-type and Tpl2 knockout male mice were initiated by a hepatic carcinogen (diethylnitrosamine, i.p. with a single dose of 25 mg.kg(-1))at 2 weeks of age, and then were given the high carbohydrate diet feeding to induce hepatic steatosis, inflammation, adenoma and HCC for 24 weeks.

Results: Tpl2 knockout mice had significantly lower incidences of liver tumor and developed hepatocellular adenoma only, which is contrast to wild-type mice where they all developed HCC. Tpl2 knockout mice had significantly down-regulated phosphorylation of JNK and ERK, and levels of mRNA expression of pro-inflammatory cytokines (Il-1β, Il-18, Mcp-1 and Nalp3), which correlated with the reduced incidence and number of hepatic inflammatory foci. Furthermore, Tpl2 ablation resulted in decreased hepatic steatosis and expression of de novo lipogenesis related markers (ACC, SCD1, SREBP1C and AKT phosphorylation), as well as reduction of endoplasmic reticulum stress biomarkers PERK and eIF-2a.

Conclusion: The study revealed for the first time that Tpl2 plays a significant role in promoting HCC development by its pro-inflammatory effect, which suggested that Tpl2 could be a molecular target for HCC prevention.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Representative pathologic lesions in livers. Hepatic lesions were assessed by H&E staining. Upper panel: Normal (Left); Steatosis and inflammatory foci (Right); Middle Panel: Hepatocellular adenoma (low magnification at x 25 and x100); Lower panel: HCC (low magnification at x25 and x200)
Fig. 2
Fig. 2
Effect of Tpl2 ablation on hepatic mRNA expression of genes related to inflammation (a) and protein phosphorylations of JNK1/2 and ERK1/2 (b). a mRNA expression of genes related to inflammatory and macrophage markers in liver tissue in mice were detected by RT-PCR analysis. Values are expressed as mean ± standard error of the mean (SEM). Actin was used as the control. b Proteins expression of JNK1/2 and ERK1/2 from liver tissue of Tpl2 knockout or wild-type mice were detected by western blotting analysis. Values are mean ± standard error of the mean (SEM). *Comparing with Tpl2 wild type group. Insets: Representative pictures of western blotting analysis
Fig. 3
Fig. 3
Effect of Tpl2 ablation on hepatic protein expressions related to lipid metabolism (a) and AKT phosphorylation (b). Proteins expression related to lipogenesis (a) and AKT phosphorylation (b) from liver tissue were determined utilizing Western blotting analysis. Data are presented as mean ± standard error of the mean (SEM). Actin was used as the control. *Comparing with Tpl2 wild type group. Insets: Representative pictures of western blotting analysis
Fig. 4
Fig. 4
Effect of Tpl2 ablation on hepatic ER stress biomarkers. Proteins expression related to ER stress were examined by western blotting analysis. Values are mean ± standard error of the mean (SEM). Actin was used as the control. *Comparing with Tpl2 wild type group. Insets: Representative pictures of western blotting analysis

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76. doi: 10.1053/j.gastro.2007.04.061. - DOI - PubMed
    1. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population. Clin Gastroenterol Hepatol. 2014 - PMC - PubMed
    1. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56(6):1384–91. doi: 10.1016/j.jhep.2011.10.027. - DOI - PubMed
    1. Duan XY, Zhang L, Fan JG, Qiao L. NAFLD leads to liver cancer: do we have sufficient evidence? Cancer Lett. 2014;345(2):230–4. doi: 10.1016/j.canlet.2013.07.033. - DOI - PubMed

Publication types

MeSH terms

Substances